ESPR's Q4 earnings lag estimates, revenues beat, stock down
Esperion Therapeutics ESPR reported earnings per share (EPS) of 22 cents for the fourth quarter of 2025, missing the Zacks Consensus Estimate of 23 cents. The company had incurred a loss of 10 cents per share (excluding loss on extinguishment of debt)...
Zacks.com